Beset by challenges with its Alzheimer’s disease drug, Biogen pivots By: MarketWatch May 03, 2022 at 12:47 PM EDT The company plans to let go of its CEO and scrap commercial plans for its controversial Alzheimer’s disease drug. Read More >> Related Stocks: Biogen Idec Sage Therapeutics, Inc. - Common Stock UnitedHealth Group